BioMap
PrivateLast Round
IPO
Mar 16, 2026
Total Funding Raised
$100M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BioMap operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a VC Round in June 2024.
BioMap is a biotechnology company that develops AI foundation models for life sciences to accelerate drug discovery and biological research.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioMap Comparables
Compare BioMap with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insilico Medicine | 85% | |
| Generate Biomedicines | 85% | |
| Chai Discovery | 84% |
For institutional investors. Book with your work email.
BioMap Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Mar 16, 2026 | ||||
| VC Round | Jun 24, 2024 | ||||
| Series A | Jul 30, 2021 |
For institutional investors. Book with your work email.
BioMap Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hong Kong Investment Corporation | VC Round |
| Lanchi Ventures | Series A |
| Legend Capital | Series A |
| BlueRun Ventures | Series A |
| Xiang He Capital | Series A |
| GGV Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 31% MoM, reaching 10.4K.
- Mar 16, 2026
Completed an IPO round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 12, 2026
BioMap and the University of Hong Kong advance the next phase of the Breast Cancer Virtual Cell Large Model project, using AI to simulate breast cancer cell functions and help researchers better understand the disease.
- is_developingNov 12, 2026
BioMap plans to work with Coyote Bioscience on an "AI + Biology" initiative that combines research translation across industry, academia, and research institutions with an open cartridge ecosystem to support molecular point-of-care testing collaboration in Hong Kong.
- partners_withNov 12, 2026
BioMap and University of Hong Kong partner to advance the project’s next phase, using AI to simulate breast cancer cell function and help researchers better understand the disease.
- is_developingNov 12, 2026
BioMap plans to collaborate with HiDream.ai on the Cross-Scale Virtual Organism Model to study biological phenomena across different scales and explore ways to predict and reconstruct their dynamics.
- is_developingNov 12, 2026
BioMap plans to work with Revvity to develop an AI biomanufacturing laboratory that integrates computational and experimental workflows in a closed loop.
For institutional investors. Book with your work email.
BioMap Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioMap's valuation, stock price, and market status.
Is BioMap a public or private company?
BioMap is a private company.
What is the current stock price of BioMap?
BioMap is a private company, so its shares have no public market price. Caplight tracks BioMap's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioMap worth (valuation)?
Valuation information for BioMap is not publicly available.
Can I buy BioMap stock?
BioMap shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioMap's last funding round?
BioMap's most recent funding round was IPO on March 16, 2026.
Who are the main investors in BioMap?
Key investors in BioMap include Hong Kong Investment Corporation, GGV Capital.
Will BioMap IPO soon?
No public IPO plans have been announced for BioMap.
How can I track BioMap secondary market activity?
Caplight tracks bids, offers, and trades in BioMap's shares on secondary markets.